Recently reported inhibitors of cyclooxygenase-2

Bibliography

• LOMBARDINO JG: Non-steroidal anti-inflammatory drugs. In: Wiley IntersciencaJohn Wiley & Sons, New York (1985).
   Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (1971) 231:232–235.
   Web of Science ®Google Scholar
• SMITH JB, WILLIL AL: Aspirin selectively inhibits prosta-glandin production in human platelets. Nature (1971) 231:235–237.
   Web of Science ®Google Scholar
• RAINSFORD KD: Side-effects of Anti-inflammatory Drugs. Rainsford KD, Velo GD (Eds.), MTP Press, Norwell, Massa-chusetts (1985) 2:343–362.
   Google Scholar
• CLIVE DM, STOFF JS: Renal syndromes associated with non-steroidal anti-inflammatory drugs. New Engl. J. Med. (1984) 310:563–572.
   PubMed Web of Science ®Google Scholar
• PIRSON Y, VAN YPERSELE DE, STRIHOU C: Renal side-effects of non-steroidal anti-inflammatory drugs: clini-cal relevance. Am. J. Kidney Dis, (1986) 8:337–344.
   Web of Science ®Google Scholar
• ALLISON MC, HOWATSON AG, TORRANCE CJ, LEE FD, RUSSEL RIG: Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. New Engl. J. Med. (1992) 327:749–754.
   PubMed Web of Science ®Google Scholar
• FENN GC, ROBINSON GC: Misoprostol - a logical thera-peutic approach to gastroduodenal mucosal injury in-duced by non-steroidal anti-inflammatory drugs? J. Pharm, Then (1991)16:385–409.
   PubMedGoogle Scholar
• FLOWER R, GRYGLEWSKI R, HERBACZYNSKACEDRA K,VANE JR: Effects of antiinflammatory drugs on prosta-glandin biosynthesis. Nature New Biol. (1972) 238:104–106.
   PubMedGoogle Scholar
• KUJUBA DA, FLETCHER BS, VARNUM BC, LIN RW, HERSCHMAN HR: T1S10, a phorbol ester tumor promoter-inducible m-RNA from Swill 3T3 cells, en-codes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. (1991) 266:12866–12872.
   Google Scholar
• MASFERRER JL, SEIBERT K, ZWEIFEL B, NEEDLEMAN P:Endogenous glucocorticoids regulate an inducible cy-clooxygenase enzyme. Proc. Natl. Acad. Sci, USA (1992) 89:3917–3921.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, ZWEIFEL B, SEIBERT K, NEEDLEMAN P: Selective regulation of cellular cyclooxygenase by dex-amethasone and endotoxin in mice. J. Din. Invest. (1990) 86:1375–1379.
   PubMed Web of Science ®Google Scholar
• HERSCHMAN HR: Review: prostaglandin synthase-2. Biochimica et Biophys, Acta. (1996) 1299:125–140.
   PubMed Web of Science ®Google Scholar
• PINTO DJ, PITTS WJ, COPELAND RA et al.: Selective inhi-bition of cyclooxygenase-2: diaryl heterocycles vs. classical NSAIDs. Med, Chem. Res. (1995) 5:394–398.
   Web of Science ®Google Scholar
• This paper provides data on the lack of selectivity of current NSAIDs as well as selectivity data on new selective COX-2 inhibitor series.
   Google Scholar
• GRISWOLD DE, ADAMS JL: Constitutive cyclooxygenase(COX-1) and inducible cyclooxygenase (COX-2): ra-tionale for selective inhibition and progress to date. Med. Res. Rev. 16:181–206.
   Google Scholar
• SEIBERT K, ZHANG Y, LEAHY K et al.: Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc. Natl. Acad. Sci, USA (1994) 91:12013–12017.
   PubMed Web of Science ®Google Scholar
• This paper provides key basic research data in support ofthe use of selective COX-2 inhibitors to provide the positive effects of pain and inflammation relief associated with non-selective COX inhibitors.
   Google Scholar
• MASFERRER JL, ZWEIFEL BS, MANNING PT et a L: Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. Proc. Natl. Acad. Sci, USA (1994) 91:3228–3232.
   PubMed Web of Science ®Google Scholar
• This paper provides evidence that selective COX-2 inhibi-tors are anti-inflammatory without displaying the gastroin-testinal side-effect profile common to all NSAIDs.
   Google Scholar
• TALLEY JJ: Selective inhibitors of cyclooxygenase-2. Exp. Opin, Then Patents (1997) 7(1):55–62.
   Web of Science ®Google Scholar
• This paper is the previous review and thus provides an ex-cellent resource to the prior patent literature.
   Google Scholar
• FUTAKI N, TAKAHASHI S, YODOYAMA M et al.: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins (1994) 47:55–59.
   PubMed Web of Science ®Google Scholar
• This discovery of NS-398 as a selective COX-2 inhibitor is one of the landmark events in the development of selective COX-2 inhibitors. The work presented led to the discovery of many similar selective COX-2 agents.
   Google Scholar
• DAVIS R, GROGDEN RN: Nimesulide, an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1994) 48:431–454.
   PubMed Web of Science ®Google Scholar
• RABASSEDA X: Nimesulide: a selective cyclooxygenase-2 inhibitor anti-inflammatory drug. Drugs Today (1996) 2:365–384
   Google Scholar
• WIESENBERG-BOTTCHER I, SCHWEIZER A, GREEN JR, SELTENMEYER Y, MULLER K: The pharmacological pro-file of CGP 28238, a highly potent anti-inflammatory compound. Agents Actions (1989) 26:240–242.
   PubMedGoogle Scholar
• CHAN CC, BLACK C, BOYCE S et al.: Pharmacology of a selective cyclooxygenase-2 inhibitor L-745,337: a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and primate stomach. I. PharmacoL Exp. Then (1995) 274:1531–1537.
   PubMed Web of Science ®Google Scholar
• This paper describes the optimisation approach used by Merck Frosst to develop one of the series of selective COX-2 inhibitors.
   Google Scholar
• GANS KR, GALBRAITH W, ROMAN RJ et al.: Anti- inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. PharmacoL Exp. Then (1990) 254:180–187.
   PubMed Web of Science ®Google Scholar
• This paper describes the impressive safety and efficacy pro-file of DuP 697,which was to become probably the most im-portant lead in the search for a selective COX-2 inhibitor.
   Google Scholar
• PENNING TD, TALLEY JJ, BERTENSHAW SR et al.: Synthe- sis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase inhibitors: identification of 4- [5-(4-methylpheny1)-3-(trifluoromethy0 -H-pyrazol-1-yllbenzene-sulfonamide (SC-58635, Celecoxib). J. Med. Chem. (1997) 40:1347–1365.
   PubMed Web of Science ®Google Scholar
• This paper provides detailed structure-activity relationships, and early PK data leading to the discovery and development of Celecoxib, one of the selective COX-2 inhibitors currently in clinical trials.
   Google Scholar
• Novel COX-2 inhibitors. Exp. Op/n. Then Patents (1995)5(4)357–359.
   Google Scholar
• BLACK WC, BAYLY C, BELLEY M et al.: From indometha-cin to a selective COX-2 inhibitor: development of in-dolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (1996) 6(6):725–730.
   Google Scholar
• This paper describes the conversion of one of the most effi-cacious NSAIDs into a selective COX-2 inhibitor.
   Google Scholar
• LEBLANC Y, BLACK WC, CHAN CC et al.: Synthesis andbiological evaluation of both enantiomers of L-761,000 as inhibitors of cyclooxygenase 1 and 2. Bioorg Med Chem. Lett. (1996) 6(6):731–736.
   Google Scholar
• COPELAND RA, WILLIAMS JM, GIANNARAS J et al.: Mecha-nism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA (1994) 91:11202–11206.
   PubMed Web of Science ®Google Scholar
• This paper provides the earliest reported data explaining thenature of 'irreversible' inhibition of COX–2.
   Google Scholar
• OULLET M, PERCIVAL MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem. J. (1995) 305:247–251.
   Google Scholar
• This paper provides kinetic data on the nature of selectiveCOX-2 inhibition and its slow reversibility.
   Google Scholar
• RIENDEAU D, PERCIVAL MD, BOYCE S et al.: Biochemical and pharmacological profile of a tetrasubstituted fu-ranone as a highly selective COX-2 inhibitor. Br. J. PharmacoL (1997) 121:105–117.
   PubMed Web of Science ®Google Scholar
• This paper provides a definitive study of the nature of selec-tive inhibition of COX-2 by 'DFU' and its slow reversibility. In addition, this paper discloses some of the variations in as-say conditions that provide different COX selectivity.
   Google Scholar
• GRISWOLD DE, ADAMS JL: Constitutive cyclooxygenase(COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med Res. Rev. 16: 191.
   Google Scholar
• SERVICE RF: Closing in on a stomach-sparing aspirinsubstitute. Science (1996) 273:1660.
   PubMedGoogle Scholar
• KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structuralbasis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644–648.
   PubMed Web of Science ®Google Scholar
• This paper provides an informative overview of the x-ray data for COX-2 and inhibitor-COX-2 complexes, and insight into some of the differences between COX-1 and -2 based upon single amino acid residue changes.
   Google Scholar
• KURUMBAIL RG, STALLINGS WC, MCDONALD JJ et al.: Crystal structure of murine cyclooxygenase-2. Prosta-glandins, Leukotrienes Essent. Fatty Acids (1006) 55 (Suppl. 1):A62, 20.
   Google Scholar
• This paper provides an informative discussion of the struc-tural/x-ray data for COX-2 and inhibitor-COX-2 complexes.
   Google Scholar
• TANAKA K, SHIMOTORI T, MAKINO S et al.: Pharma-cological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4 H-1-benzopyran-4-one. Arzneim.-Forsch. Drug Res. (1992) 42:935–945.
   PubMed Web of Science ®Google Scholar
• REITZ DB, LI JJ, NORTON MB et al.: Selective cyclooxyge-nase inhibitors: novel 1,2-diarylcyclopentenes are po-tent and orally active COX-2 inhibitors. J. Med. Chem. (1994) 37:3878–3881.
   PubMed Web of Science ®Google Scholar
• THIERIEN M, BRIDEAU C, CHAN C-C et al.: Synthesis and biological evaluation of 5,6-diarylimidaxo [2.1-b]thia-zole as selective COX-2 inhibitors. Bioorg. Med. Chem. Lett. (1997) 7(1)47–52
   Google Scholar
• TRIMBLE LA, CHAURET N, SILVA JM, NICOLL-GRIFFITHDA, LI C-S, YERGEY JA: Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766,112. Bioorg. Med. Chem. Lett. (1997) 7(0:53–56.
   Google Scholar
• ROY P, LEBLANC Y, BALL RG et al.: A new series of selec-tive COX-2 inhibitors: 5,6-diarylthiazolo [3,2-b] [1,2,4]triazoles. Bioorg. Med. Chem. Lett. (1997) 7(1):57–62.
   Web of Science ®Google Scholar
• This paper describes a new series of selective COX-2 inhibi-tors which have met many of the criteria for more extensive research. The previous papers in the series give the reader insight into the complexity of drug discovery including metabolic fate as a determinant of utility.
   Google Scholar
• WOODS KW, MCCROSKEY RW, MICHAELIDES MR, WADACK, HULKOWER KI, BELL RL: The design and synthesis of novel cyclooxygenase-2 inhibitors. 214th ACS Na-tional Meeting, Las Vegas NV, September 7–11 (1997). Poster Medi 92.
   Google Scholar
• LAZER ES, SORCEK R, CYWNI CL et al.: Anti-inflammatory 2-benzy1-4-sulfony1-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2. 214th ACS Na-tional Meeting, Las Vegas NV, September 7–11 (1997). Poster Medi 93.
   Google Scholar
• Celecoxib. Drugs Future (1997) 22(7):711–714.
   Google Scholar
• This paper describes both the structure and activity of one ofthe COX-2 inhibitors currently in development.
   Google Scholar
• LANZA FL, RACK MF, CALLAIS DA at al.: A pilot endo-scopic study of the gastroduodenal effects of SC- 58635k a novel COX-2 selective inhibitor. Dig, Dis, Week, Washington, DC, May 10–16 (1997). Abstract 400.
   Google Scholar
• MEHLISCH DR, HUBBARD RC, ISAKSON P, KARIM A, WEAVER M, MILLS S: Analgesic efficacy and plasma lev-els of a highly selective inhibitor of COX-2 (SC-58635) in patients with post-surgical dental pain. 8th World Congress on Pain, Vancouver, August 17–22 (1996) 288.
   Google Scholar
• HUBBARD RC, MEHLISCH DR, JASPER DR, NUGENT MJ, YU S, ISAKSON PC: SC-58635, a highly selective inhibi-tor of COX-2, is an effective analgesic in an acute post-surgical pain model. J. Invest. Med. (1996) 44(3):293A.
   Google Scholar
• HUBBARD RC, KOEPP RJ, YU S et al.: SC-58635 (Cele-coxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pi-lot study. Arthritis Rheum. (1996) 39\(Suppl. 9). Abstract 1188.
   Google Scholar
• TSUJII M, KAWANO S, SAWAOKA H et al.: Evidences for involvement of cyclooxygenase-2 in proliferation for two gastrointestinal cancer cell lines. Prostaglandins, Leukotrienes, Essent. Fatty Acids (1996) 55 (3):179–183.
   Google Scholar
• PARRETT ML, HARRIS RE, JOARDER FS, ROSS MS, CLAUSEN KP, ROBERTSON FM: Cyclooxygenase-2 gene expression in human breast cancer. Intern. J. OncoL (1997) 10(3):503–507.
   Google Scholar
• SHENG H, SHAO J, KIRKLAND SC et al.: Inhibition of co-lon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Din, Invest (1997) 99(9):2254–2259.
   PubMed Web of Science ®Google Scholar
• TSUJII M, KAWANO S, DUBOIS RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA (1997) 94 (7):3336–3340.
   PubMed Web of Science ®Google Scholar
• REDDY BS, RAO CV, SEIBERT K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopre-ventive properties in colon carcinogenesis. Cancer Res. (1996) 56(20):4566–4569.
   PubMed Web of Science ®Google Scholar
• This paper presents new, compelling evidence for use of aselective COX-2 inhibitor as a preventative therapy for colon cancer.
   Google Scholar